FGFR1 and neoplasm: Within the breast cohort, 3/11 patients showed some evidence of tumour shrinkage, with one FGFR2-amplified TNBC patient showing a prolonged partial response to futibatinib treatment, leading to further characterization of this drug in an ongoing phase 2 study (FOENIX, NCT04024436) in FGFR1- and FGFR2-amplified triple negative or hormone receptor-positive breast cancer.